Drug intelligence / Profile preview

GamEvac-Combi

Development stage: Phase 4
Lead developer: Gamaleya Center
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GamEvac-Combi is a heterologous prime-boost vaccine developed against Ebola virus disease (EVD). The vaccine consists of two components: a live-attenuated recombinant vesicular stomatitis virus (VSV) expressing Ebola virus glycoprotein, used as the prime, and a recombinant adenovirus serotype-5 (Ad5) also expressing Ebola virus glycoprotein, used as the boost[1][5]. This vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia[4][5]. The vaccine targets the Makona variant of Ebola virus that circulated during the 2013-2016 West Africa outbreak[5].

Brand names: GamEvac-Combi
Other names: ГамЭвак-Комби

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on GamEvac-Combi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GamEvac-Combi.

Explore the full profile